Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma

This trial was supported by grants from the Science Fund for Creative Research Groups of the National Natural Science Foundation of China (82521003 to Y.S.), the National Natural Science Foundation of China for Excellent Young Scientists Fund (82522065 to J.L.), the National Natural Science Foundation of China (82441026 to Y.S., 92259202 to Y.S. and 81803105 to J.-B.L.), the Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China (JYB2025XDXM611 to J.M.), the Guangdong Basic and Applied Basic Research Foundation (2024A1515030248 to G.-Q.Z.), the Young Talents Program of SYSUCC (YTP-SYSUCC-0103 to J.L.), the Cancer Innovative Research Program of SYSUCC (CIRP-SYSUCC-0010 to Y.S.), the Overseas Expertise Introduction Project for Discipline Innovation (111 Project) (B14035 to J.M.) and the National Medical Research Council Singapore Clinician Scientist Award (NMRC/CSA-INV/0027/2018, CSAINV20-nov-0021 to M.L.K.C.). We thank all of the participants and their families in this study. We also thank Innovent Pharmaceutical for providing free sintilimab and logistical support for all participants; J. T. S. Wee and T. S. Huey for their insightful comments on the trial design; and Y.-X. Li, X.-Z. Chen and Y. Guo for their contributions as members of the independent data monitoring committee. The trial sponsors did not have roles in data collection, interpretation or manuscript preparation.